Global Clostridium Diagnostics Market 2017-2021
About Clostridium Diagnostics
Clostridium is a gram-positive bacteria that belongs to the Firmicutes phylum. There are multiple species of Clostridium — Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, and Clostridium sordellii, which are responsible for numerous infections. Clostridium tetani is responsible for tetanus, Clostridium botulinum causes botulism, Clostridium perfringes leads to gas gangrene, Clostridium sortellii causes pneumonia, endocarditis, arthritis, peritonitis, and myonecrosis, and Clostridium difficile is responsible for diarrhea. Technavio’s analysts forecast the global clostridium diagnostics market to grow at a CAGR of 14.71% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global clostridium diagnostics market for 2017-2021. To calculate the market size, the report considers the sales/volume/value.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Clostridium Diagnostics Market 2017-2021
Technavio recognizes the following companies as the key players in the global clostridium diagnostics market : Abbott, Beckman Coulter, Olympus, Siemens Healthineers, and F. Hoffmann-La Roche.
Other Prominent Vendors in the market are: BD, bioMerieux, Chrono-log Corporation, Corgenix, Diazyme Laboratories, FUJIREBIO DIAGNOSTICS, Hologic, QIAGEN, Sysmex Corporation, and Thermo Fisher Scientific.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is technological advancements. The use of automation and robots in clinical laboratories has become more prevalent today. The pressure on the laboratories to produce faster results and reduce errors to improve patient care has increased. The current technologies in laboratory automation can automate specimen transportation, sorting, accessioning, and inspection. Over the decade, the pressure to reduce healthcare costs has increased, and hence, laboratories are relying on automation to maintain profitability. Currently, over 30% of laboratories in Japan, Europe, and North America has implemented a significant degree of laboratory automation.”
According to the report, one of the major drivers for this market is Rising prevalence of Clostridium-related diseases. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. It is estimated that patients with CDI put a burden of $3.2 billion annually in the US on the healthcare system. Patients with CDI have a longer stay at the hospital, and CDI has been the major cause of large outbreaks of diseases in hospitals. The new molecular diagnostic stool test will replace the current enzyme immunoassay tests.
Further, the report states that one of the major factors hindering the growth of this market is High cost of molecular diagnostics over immunoassays. Most of the tests done for the diagnosis of Clostridium-related infections are immunoassay tests as they are cost-effective. Immunoassays are quick and accurate tests and can be done on-site, as well as, in the laboratory. The tests are very effective in detecting several infections. Every year out of 100 cases, 30 cases go undiagnosed. With 30% chances of missing the diagnosis, the other preferable option is molecular diagnostics that offer high accuracy. With several organizations preferring molecular diagnostics over immunoassays, patients have to incur high costs.
Abbott, Beckman Coulter, Olympus, Siemens Healthineers, F. Hoffmann-La Roche, BD, bioMerieux, Chrono-log Corporation, Corgenix, Diazyme Laboratories, FUJIREBIO DIAGNOSTICS, Hologic, QIAGEN, Sysmex Corporation, and Thermo Fisher Scientific.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook